Anacura, a Ghent, Belgium-based company offering medical and pharmaceutical analytical services, acquired OHMX.bio, a Ghent University spin-off specialized in advanced -omics technology.
The amount of the deal was not disclosed.
The acquisition expands the existing anacura group activities at AnaBioTec and Labo Nuytinck towards drug discovery and diagnostics research.
Established in 2019, and led by CEO and CSO Gerben Menschaert, as a Ghent University spin-off, OHMX.bio operates as a study design company, specializing in -omics technologies for discovery and (pre)clinical studies. The company combines multi-omic technologies, such as sequencing, in combination with advanced bio-informatics to speed up the discovery process and quality control of biologics and advanced therapy medicinal products (ATMPs) such asmRNA vaccines and CAR-T cells.
Led by CEO Griet Nuytinck, Anacura is an independent laboratory group with more than 250 dynamic employees based in Evergem (Ghent) and Bruges. Active in various areas of healthcare, Anacura operates daughter companies AnaBioTec and Labo Nuytinck, which deliver end-to-end analytical drug development solutions for pharma and biotech clients, and lab services for patients and healthcare providers, respectively.
FinSMEs
05/07/2024